Mode
Text Size
Log in / Sign up
N/A N=20 Treatment

Measurement of Bispectral Index and Awareness in Patients Undergoing Electrophysiology Studies With Isoproterenol

Intraoperative Awareness

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Feb 2015
Primary outcome: Primary: Number of Participants With an Increase in BIS Readings During Steady State — 19 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Isoproterenol (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
NYU Langone Health
Primary completion
Sep 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With an Increase in BIS Readings During Steady State
19
PRIMARY
BIS Change
24.6
SECONDARY
Number of Participants With Spontaneous Musculoskeletal Movement
12
SECONDARY
Number of Participants Who Follow Verbal Command to Squeeze Hands
10

Summary

Isoproterenol is used as a cardiac stimulant in electrophysiology studies (EP). Preliminary data suggests that administration of isoproterenol increases the Bispectral index (BIS). BIS is used to monitor neuronal signals under anesthesia. The BIS level is suggested to correspond to the level of consciousness. We hypothesize that isoproterenol increases BIS values because it increases the patient's level of consciousness through its central nervous system (CNS) stimulatory effects. In this study, we will administer increasing doses of isoproterenol to EPS patients. We will measure the BIS levels continuously before and after isoproterenol administration. In addition, we will test the level of awareness of patients by their response to a modified isolated forearm technique.

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for EP studies for catheter ablation of atrial fibrillation under general anesthesia will participate in the study

Exclusion Criteria

  • Patients with neuromuscular disease precluding the use of succinylcholine will be excluded.
  • Patient or cardiologist refusal
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01377636). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search